07:00 , Aug 10, 2009 |  BC Week In Review  |  Company News

Debiopharm S.A., Curis, Mercury Therapeutics deal

Debiopharm added to its preclinical programs this week with two deals. Curis granted Debiopharm an exclusive, worldwide license to develop and commercialize its heat shock protein 90 (Hsp90) technology, which includes CUDC-305 and back-up compounds....